Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,801–7,900 of 15,747
Case report: Five patients with myocarditis after mRNA COVID-19 vaccination
Murase, H., Zhu, Y., Sakaida, K., Mizuno, H., Mori, H., Iwayama, H., Suzuki, N., Nagai, N., & Okumura, A. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.977476 · Cited by 9
Skowronski, D., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J., Galanis, E., Naus, M., Patrick, D., Sbihi, H., Adam, S. E., et al. (2021) · medRxiv · doi:10.1101/2021.06.07.21258332 · Cited by 30
“When RCT data were re-analyzed applying the usual two-week lag for vaccine effect, a single dose of either product was also substantially protective at 92-93% [3,4].”
MethodU.S. adults’ reasons for changing their degree of willingness to vaccinate against COVID-19
Koskan, A. M., Teeter, B. S., Daniel, C. L., LoCoco, I. E., Jensen, U. T., & Ayers, S. L. (2023) · Journal of Public Health · doi:10.1007/s10389-023-01819-2 · Cited by 8
“…in the U.S. (Amin et al. 2022), representing significant mortality considering the broad public availability of vaccines that are up to 95% effective in preventing new infections and that significantly reduce the risk of hospitalization and infection-associated complications (Polack et al. 2020).”
Fayad, D., & Frenck, R. W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010087 · Cited by 12
“…Based on the safety and immunogenicity of the 30 µ g dosage of BNT162b2 in adults, along with the supposition that 16-year-olds physiologically and morphologically are very similar to adults, the initial COVID-19 vaccine trial in adults was expanded to adolescents at least 16 years of age [38].”
BackgroundResultSelf-citationBoikova, A., Quaife-Ryan, G. A., Batho, C. A. P., Lawrence, E., Robinson, H., Ascanelli, C., Jennbacken, K., Wang, Q., Hansson, K. M., Seaton, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.02.551469 · Cited by 7
COVID-19 vaccination and venous thromboembolism risk in older veterans
Elkin, P. L., Brown, S. H., Resendez, S. D., McCray, W., Resnick, M., Hall, K. C., Franklin, G., Connors, J. M., & Cushman, M. (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.527 · Cited by 8
“Pfizer monitored adverse reactions in 21,720 vaccine recipients and 21,728 placebo recipients [7].”
BackgroundNeutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited sera
(2021) · doi:10.21203/rs.3.rs-540721/v1 · Cited by 341
Pohl, M. O., Busnadiego, I., Marrafino, F., Wiedmer, L., Hunziker, A., Fernbach, S., Glas, I., Moroz, E., Hale, B. G., Caflisch, A., et al. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001625 · Cited by 8
Cutaneous adverse reactions following the Pfizer/ BioNTech COVID ‐19 vaccine
Luo, A., & Oakley, A. M. (2022) · Australasian Journal of Dermatology · doi:10.1111/ajd.13859 · Cited by 8
Advances in the computational analysis of SARS-COV2 genome
Machado, J. A. T., Rocha-Neves, J. P., Azevedo, F., & Andrade, J. P. (2021) · Nonlinear Dynamics · doi:10.1007/s11071-021-06836-y · Cited by 9
Dimeglio, C., Milhes, M., Loubes, J., Ranger, N., Mansuy, J., Trémeaux, P., Jeanne, N., Latour, J., Nicot, F., Donnadieu, C., et al. (2021) · Viruses · doi:10.3390/v13050898 · Cited by 11
“The theoretical efficacy of vaccination was set at 94%, as stated by the Pfizer trial [5], and we considered a subject to be immunized 7 days after the second dose (28 days after the first injection).”
BackgroundCamacho-Moll, M. E., Mata-Tijerina, V., Gutiérrez-Salazar, C. C., Silva-Ramírez, B., Peñuelas-Urquides, K., González-Escalante, L. A., Escobedo-Guajardo, B. L., Luna, J. E. C., Corrales-Pérez, R., Gómez-García, S., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1402527 · Cited by 8
Mead, M. N., Seneff, S., Wolfinger, R. D., Rose, J., Denhaerynck, K., Kirsch, S., & McCullough, P. A. (2024) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/fdrasy50 · Cited by 22
Choi, J. Y., Lee, Y., Park, N. G., Kim, M. S., & Rhie, S. J. (2024) · Pharmaceuticals · doi:10.3390/ph17030356 · Cited by 8
“Particularly, within the special situation of a pandemic, when serious AEFIs such as death are reported by the media, the public’s trust in vaccines decreases due to fear of potential AEFIs, which might lead to the rejection of, or hesitancy in, vaccines [4,5].”
BackgroundImpact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States
Fang, F., Clemens, J. D., Zhang, Z., & Brewer, T. F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301830 · Cited by 10
Fisher, W. S., Douglas, J., Roshan, S., Perez, R., Wei, S., Roberts, L., Ewert, K. K., & Safinya, C. R. (2025) · Langmuir · doi:10.1021/acs.langmuir.4c04297 · Cited by 11
Pakvisal, N., Sainamthip, P., Teeyapun, N., Luangdilok, S., Wanlapakorn, N., Yorsaeng, R., Poovorawan, Y., Pakvisal, P., Susiriwatananont, T., Zungsontiporn, N., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2094149 · Cited by 6
Mahfouz, M. S., Abdelmageed, M. M., Alqassim, A. Y., Hakami, T. K. M., Alshekh, M. M., Hamithi, D., Alakhdar, F. D. H., Ayyashi, N. M., & Madkhali, R. M. A. (2023) · Open Medicine · doi:10.1515/med-2023-0804 · Cited by 16
“Moreover, clinical trials of the current COVID-19 vaccines did not collect MC outcomes postvaccine [43].”
BackgroundNiekrens, V., Esse, J., Held, J., Knobloch, C. S., Steininger, P. A., Kunz, B., Seggewies, C., & Bogdan, C. (2022) · Vaccines · doi:10.3390/vaccines10050650 · Cited by 8
“Age boundaries were chosen in accordance with previous clinical trials [9,10].”
BackgroundMethodResultInfluentialTherapeutic Application of mRNA for Genetic Diseases
Schürmann, P. J. L., Vriesman, S. V. B., Castro-Alpízar, J., Kooijmans, S. A. A., Nieuwenhuis, E. E. S., Schiffelers, R. M., & Fuchs, S. A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70019 · Cited by 14
“This status quo changed during the coronavirus 2019 (COVID-19) pandemic with the unprecedented rapid development of the first two COVID-19 mRNA vaccines (BioNTech BNT162b2 and Moderna mRNA-1273) (Baden et al. 2021; Polack et al. 2020).”
InfluentialPanìco, A., Lobreglio, G., Bagordo, F., Zizza, A., Donno, A. D., Rosato, C., Lazzari, R., Chicone, M., Indino, F., Recchia, V., et al. (2022) · Vaccines · doi:10.3390/vaccines10060862 · Cited by 8
Pietroluongo, E., Placido, P. D., Tortora, M., Martinelli, C., Viggiano, A., Saponaro, M. R., Caltavituro, A., Buonaiuto, R., Morra, R. P., Ottaviano, M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.06.015 · Cited by 10
Alhashimi, M., Sayedahmed, E. E., Elkashif, A., Chothe, S. K., Wang, W.-C., Murala, M. S. T., Gairola, V., Wakamatsu, N., Gontu, A., Ramasamy, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01198-7 · Cited by 10
Hong, W., Cheng, P., Yang, H. J., Shi, H., Wang, Z., Li, J., Hong, L., Peng, D., He, C., Ren, W., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01517-2 · Cited by 14
Rama, T. A., & Álvarez-Twose, I. (2021) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0680 · Cited by 8
Cutaneous reaction to BNT162b2 mRNA COVID‐19 vaccine
Valle, A. L., Falkenhain‐López, D., & Ruiz‐Arranz, C. (2021) · International Journal of Dermatology · doi:10.1111/ijd.15575 · Cited by 8
Wassif, M., Lo, P., Satouris, P., Swan, L., Tardo, D. T., Kovacic, J. C., Muller, D. W., Muthiah, K., Kotlyar, E., & Bart, N. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.01.002 · Cited by 11
Scope of SARS-CoV-2 variants, mutations, and vaccine technologies
Wambani, J., & OKOTH, P. K. (2022) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-022-00121-z · Cited by 12
“For the virus to enter alveolar cells via the ACE2 receptor, it is completely reliant on the spike protein [7, 63].”
BackgroundMethodThe Role of Biological Sex in Pre-Clinical (Mouse) mRNA Vaccine Studies
Binici, B., Rattray, Z., Schroeder, A., & Perrie, Y. (2024) · Vaccines · doi:10.3390/vaccines12030282 · Cited by 13
“Similarly, whilst the initial reports on the safety and efficacy of two mRNA lipid nanoparticles (LNPs)- based vaccines [19,20] did not fully provide sex-based data [21].”
ResultSafety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
Agrati, C., Castilletti, C., Battella, S., Cimini, E., Matusali, G., Sommella, A., Sacchi, A., Colavita, F., Contino, A. M., Bordoni, V., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00531-8 · Cited by 9
Filon, F. L., Lazzarato, I., Patriarca, E., Iavernig, T., Peratoner, A., Perri, G., Ponis, G., Rocco, G., & Cegolon, L. (2022) · Vaccines · doi:10.3390/vaccines10101616 · Cited by 9
Zhang, K., Xu, Z. C., Xiao, Z., Cao, F., Wang, J., Xu, Y., Ma, W. M. J., Long, S., & Zha, G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101893 · Cited by 10
“The emergence of mRNA therapeutics has significantly advanced the field of vaccinology, as demonstrated by the clinical success of lipid nanoparticle (LNP)-based COVID-19 vaccines [1].”
Klinkhardt, U., Schunk, M., Ervin, J. E., Schindler, C., Sugimoto, D. H., Rankin, B. M., Amann, R., Monti, M., Kutschenko, A., Schumacher, C., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2410574 · Cited by 9
Current evidence of COVID-19 vaccination-related cardiovascular events
Khiali, S., Rezagholizadeh, A., Behzad, H., Baghi, H. B., & Entezari‐Maleki, T. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2022.2161249 · Cited by 8
“pressure as comorbidity) and individuals with normal blood pressure (BP) from the viewpoint of COVID-19 vaccine efficacy [92].”
BackgroundNiesen, M. J. M., Matson, R., Puranik, A., O’Horo, J. C., Pawlowski, C., Vachon, C. M., Challener, D. W., Virk, A., Swift, M. D., Speicher, L. L., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac042 · Cited by 7
“Furthermore, the estimates of VE for the 3-dose regimens in the time period 4 to 11 months following full vaccination are comparable to the estimates of VE for the 2-dose regimens in the time period 1 to 2 months following full vaccination and those reported in initial clinical trials (5, 6).”
BackgroundResultmRNA-1273 is placenta-permeable and immunogenic in the fetus
Chen, J., Hsu, M., Kuo, R., Wang, L., Kuo, M., Tseng, L.-Y., Chang, H., & Chiu, C. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102489 · Cited by 10
Screening lipid nanoparticles using DNA barcoding and qPCR
Liu, D., Wang, X., Xu, L., Al-Delfi, Z., Mekonnen, Z. A., Gao, S., Grubor‐Bauk, B., & Zhao, C. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114598 · Cited by 11
Long-Lasting Enhanced Cytokine Responses Following SARS-CoV-2 BNT162b2 mRNA Vaccination
Cabău, G., Badii, M. O., Mirea, A.-M., Gaal, O. I., van Emst, L., Popp, R. A., Crișan, T. O., & Joosten, L. A. B. (2024) · Vaccines · doi:10.3390/vaccines12070736 · Cited by 12
Petro, C. D., Hooper, A. T., Peace, A., Mohammadi, K. A., Eagan, W., Elbashir, S. M., DiPiazza, A. T., Makrinos, D. L., Pascal, K. E., Bandawane, P., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn0396 · Cited by 9
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response
Qiao, Y., Wotring, J. W., Zheng, Y., Zhang, C. J., Zhang, Y., Jiang, X., Pretto, C. D., Eyunni, S., Parolia, A., He, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221809120 · Cited by 8
D’Onofrio, L., Fogolari, M., Amendolara, R., Siena, A., Fata, R. D., Davini, F., Coraggio, L., Mignogna, C., Moretti, C., Maddaloni, E., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3601 · Cited by 10
“The development and administration of large‐scale SARS‐CoV2 vaccines have been a turning point in the management of Covid‐ 19.(7,8) Nevertheless, impaired response to vaccination in subjects with diabetes has been reported(9) and poor glycaemic control seems to be a detrimental risk factor in this regard.”
BackgroundBánki, Z., Seekircher, L., Falkensammer, B., Bante, D., Schäfer, H., Harthaller, T., Kimpel, J., Willeit, P., von Laer, D., & Borena, W. (2022) · Viruses · doi:10.3390/v14081642 · Cited by 8
“Consistent with previous studies, we found that two BNT162b2 vaccinations result in a robust antigen-specific IgG response in all investigated participants, which is in contrast to natural infections where antibody titer correlates with severity and seroconversion might even be absent, especially in some asymptomatic…”
ResultAcute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination
Ishioka, Y., Makiguchi, T., Itoga, M., Tanaka, H., Taima, K., Goto, S., & Tasaka, S. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.08.2213 · Cited by 9
“According to the World Health Organization global pharmacovigilance database, 678 cases of suspected ILD, 159 cases of suspected organizing pneumonia, 12 cases of acute lung injury, and two cases of acute interstitial pneumonitis after BNT162b2 vaccine were reported, whereas no case of AE-ILD was included.7 In additio…”
BackgroundInfluentialPan‐Hammarström, Q., & Casanova, J. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13628 · Cited by 11
Slamanig, S., Lemus, N., Lai, T. Y., Singh, G., Mishra, M., Abdeljawad, A., Boza, M., Dolange, V., Singh, G., Lee, B., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126586 · Cited by 9
Picture of the Favourable Immune Profile Induced by Anti-SARS-CoV-2 Vaccination
Lanuti, P., Rossi, C., Cicalini, I., Pierdomenico, L., Damiani, V., Semeraro, D., Verrocchio, S., Boccio, P. D., Evangelista, A., Sarra, A., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9081035 · Cited by 8
“In particular, the BNT162b2 vaccine is formulated as an RNA–lipid nanoparticle of nucleosidemodified mRNA (modRNA) [1].”
BackgroundLutz, C. S., Hartman, R. M., Vigil, D. E., Britton, A., Burrage, A. B., Campbell, A. P., Close, R. M., Desnoyers, C., Dobson, J., Garcia, S., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad172 · Cited by 9
Self-citationManaging adult asthma during the COVID-19 pandemic: A 2022 review and current recommendations
Ong, K. Y., Tiew, P. Y., & Koh, M. S. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202285 · Cited by 8
Immunotherapy for neuroblastoma using mRNA vaccines
Ahmed, T. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100033 · Cited by 10
Reyes, C. T., Cao, W., Astorini, A. G., Drohan, M. M., Schulz, C. T., Shuster, C. L., Robbins, M. L., Yang, M., & Stamates, A. L. (2023) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2023.2248236 · Cited by 8
Chiba, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256151 · Cited by 9
“susceptibility of those who have received the first and second doses decreases by 80% and 95%, respectively, compared to those who have not been vaccinated [27, 28].”
BackgroundRolfes, M. A. R., Talbot, H. K., Morrissey, K. G., Stockwell, M. S., Maldonado, Y., Nguyen, H. Q., Lutrick, K., Bowman, N. M., Rao, S., Izurieta, H. S., et al. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae334 · Cited by 15
Suhandynata, R., Bevins, N., Tran, J., Huang, D.-L., Hoffman, M., Lund, K., Kelner, M., Mclawhon, R., Gonias, S., Nemazee, D., et al. (2021) · medRxiv · doi:10.1101/2021.03.10.21253299
Waning antibodies to SARS-CoV-2 – Don't panic
Meyer, B. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100115 · Cited by 9
“Interestingly, the efficacy trials for mRNA vaccines have shown that protection from symptomatic COVID-19 disease starts around 10-12 days after administration of the first dose, i.e. at a time when there are very few neutralizing antibodies present indicating that the induction of T-cell responses likely play a role…”
InfluentialDuro, M., Almeida, C., Duro, I., & Sarmento, A. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-03044-4 · Cited by 8
“The currently available COVID-19 vaccines have been reported to be highly effective in preventing symptomatic infection and/or hospitalization in clinical trials [24, 25].”
BackgroundAhn, J. Y., Ko, J., Peck, K. R., Bae, S., Kim, S., Lee, K. H., Song, Y. G., Kim, Y. C., Park, Y. S., Song, K., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad363 · Cited by 8
“Reactogenicity data after the third vaccinations were collected for 7 days using an electronic diary format, which was developed based on phase 3 clinical trials of vaccines [2, 9].”
MethodYe, X., Huang, C., Yan, V. K. C., Kang, W. C. M., Fan, M., Tsang, G. K. C., Ho, C. M. Y., Lip, G. Y. H., Yiu, K., Tse, H., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad015 · Cited by 8
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Zhang, L., More, K., Ojha, A., Jackson, C., Quinlan, B., Li, H., He, W., Farzan, M., Pardi, N., & Choe, H. (2023) · doi:10.21203/rs.3.rs-3186627/v1 · Cited by 243
Grandinetti, R., Palazzolo, E., Rizzo, L., Carbone, R., Pisi, G., Fainardi, V., & Esposito, S. (2023) · Microorganisms · doi:10.3390/microorganisms11071745 · Cited by 8
Segni, M. T., Demissie, H. F., Kaso, M., Geleto, A. K., Kelkile, M. W., Sori, B. K., Heyi, M. L., Iticha, D. G., Shumi, G., Guddisa, A. B., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278334 · Cited by 8
Schubert, L., Koblischke, M., Schneider, L., Porpaczy, E. A., Winkler, F., Jaeger, U., Blüml, S., Haslacher, H., Burgmann, H., Aberle, J. H., et al. (2022) · Cancers · doi:10.3390/cancers14081962 · Cited by 10
“However, patients with hematological diseases were excluded from the corresponding clinical trials [3,4].”
BackgroundRane, M. S., Robertson, M. M., Kulkarni, S., Frogel, D., Gainus, C., & Nash, D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.039 · Cited by 8
“We compared vaccine-induced and infection-induced protection separately for each vaccine product (Pfizer-BioNTech BNT162b2, Moderna mRNA-1273, and Janssen Ad26.”
O’Reilly, S. R., Byrne, J., Feeney, E. R., Mallon, P. W. G., & Gautier, V. (2024) · Vaccines · doi:10.3390/vaccines12101089 · Cited by 11
“Early clinical trials established assessed vaccine efficacy and CoPs for regulatory and clinical decision making [95,107,207].”
BackgroundAcceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer
Couderc, A., Ninove, L., Nouguerède, E., Rey, D., Rebroin, M., Daumas, A., Tomasini, P., Greillier, L., Salas, S., Duffaud, F., et al. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.05.002 · Cited by 10
“The first data on vaccination in patients with cancer stated a low acceptation rate [12,13] and at best, a mild intention rate for the COVID-19 vaccine [14,15].”
Advances in vaccine development for human trichuriasis
Hayon, J., Weatherhead, J. E., Hotez, P. J., Bottazzi, M. E., & Zhan, B. (2021) · Parasitology · doi:10.1017/s0031182021000500 · Cited by 10
Yasmin, S., Ansari, M. Y., Pandey, K., & Dikhit, M. R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130754 · Cited by 8
Yen, F., Wang, S., Lin, S., & Wei, J. C. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110692 · Cited by 7
“The ‘gold-standard ’ evidence showed that COVID-19 vaccines begin to work 10 – 14 days after vaccination, so we used a 14-day washout period after the index date for measuring outcomes to avoid reverse causality [21].”
MethodWang, X., Gotchev, D., Fan, K. Y., Vega, M. M., Mani, N., McGovern-Gooch, K. R., Cuconati, A., Tercero, B., Wang, X., Carpino, P. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02009 · Cited by 8
Kain, D. C., Stall, N. M., Allen, V. G., Evans, G. A., Hopkins, J. P., Kouyoumdjian, F. G., McGeer, A., Mubareka, S., Patel, S. N., Rochon, P. A., et al. (2021) · doi:10.47326/ocsat.2021.02.15.1.0 · Cited by 8
Lü, T., Chen, A., Li, C., Li, K., Wang, S., Zhang, Y., Yang, B., Wang, J., Gong, Q., Li, A., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf963 · Cited by 10
“In vitro transcribed messenger RNA (IVT mRNA) is extensively utilized in gene gain-of-function studies and serves as a fundamental component in mRNA-based therapies, with mRNA vaccines against S AR S-CoV-2 being the most notable example [ 1 , 2 ].”
Katz, J., Labilloy, A., & Lee, A. (2022) · BMC Pediatrics · doi:10.1186/s12887-022-03561-2 · Cited by 9
Antiphospholipid syndrome in the era of COVID-19 – Two sides of a coin
Mahroum, N., Habra, M., Alrifaai, M. A., & Shoenfeld, Y. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103543 · Cited by 9
Lemieux, J. E., Li, A., Gentili, M., Perugino, C. A., Weiss, Z., Bowman, K. A., Ankomah, P., Liu, H., Lewis, G. D., Bitar, N., et al. (2021) · medRxiv · doi:10.1101/2021.07.11.21260338 · Cited by 11
Future developments in the prevention, diagnosis and treatment of COVID-19
Coltart, C. E. M., & Collet-Fenson, L. B. (2021) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2021.03.012 · Cited by 11
Izak, M., Stoyanov, E., Dezuraev, K., & Shinar, E. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.082 · Cited by 8
“In contrast to finding of Polack et al [1] younger individuals reported less adverse events: 69.”
BackgroundResultInfluentialSide Effects of Mixing Vaccines against COVID-19 Infection among Saudi Population
Alshahrani, M. M., & Alqahtani, A. (2022) · Vaccines · doi:10.3390/vaccines10040519 · Cited by 11
“The majority of COVID-19 vaccines were shown to be safe and effective against SARS-CoV-2 [8,13,14,17].”
BackgroundInfluentialSevere COVID-19 vaccine associated myocarditis: Zebra or unicorn?
HENDREN, N. S., Carter, S. J., & Grodin, J. L. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.09.036 · Cited by 8
Unlock the sustained therapeutic efficacy of mRNA
Cao, D., Tian, M., Liu, Z., Guo, K., Peng, J., Ravichandra, A., Ferrell, C., & Dong, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113837 · Cited by 10
Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
Henze, L., Braun, J., Meyer‐Arndt, L., Jürchott, K., Schlotz, M., Michel, J., Grossegesse, M., Mangold, M., Dingeldey, M., Kruse, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1056525 · Cited by 10
“Although the efficacy of mRNAbased vaccines remained unmet, their need for deep cooling and challenging production limits their global usage (5, 19).”
BackgroundYang, H., Gao, Z., Zhou, Y., Ge, X., Pan, X., Li, J., Zhang, Z., Jin, X., Liu, G., He, Z., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113892 · Cited by 13
Overview of Reported Breast Implant–Related Reactions After COVID-19 Infection or Vaccination
Mahrhofer, M., Weitgasser, L., & Schoeller, T. (2022) · Aesthetic Surgery Journal · doi:10.1093/asj/sjac101 · Cited by 8
Quek, A. M. L., Wang, S., Teng, O., Shunmuganathan, B. D. O., Er, B. G. C., Mahmud, N. F. B., Ng, I. X. Q., Gupta, R., Tan, I. S. L., Tan, N. Y., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106238 · Cited by 12
Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study
Palaia, I., Caruso, G., Donato, V. D., Vestri, A., Napoli, A., Perniola, G., Casinelli, M., Fegatelli, D. A., Campagna, R., Tomao, F., et al. (2021) · Vaccines · doi:10.3390/vaccines10010012 · Cited by 8
Zimmer, D. N., Schmid, F., & Settanni, G. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c05057 · Cited by 12
Chohan, H. K., Jamal, A., Mubeen, M., Khan, M. U., Junaid, M., Chohan, M. K., Imran, A., Aslam, A., Anwar, A., & Hashmi, A. A. (2023) · Cureus · doi:10.7759/cureus.38564 · Cited by 11
BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety
Alkhalil, E., Jarad, B., Saleh, T. A., Aldarwish, W., & Joujeh, D. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.292 · Cited by 8
“The safety profile observed over a median of two months was similar to that of other viral vaccines, paving the way for the progression of the BNT162b2 vaccine candidate into phase 3 [89] (NCT04368728).”
Nanomedicine approaches against SARS-CoV-2 and variants
Zhang, H., Liu, Y., & Liu, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.004 · Cited by 9
Essink, B. J., Shapiro, C., Isidro, M. G. D., Bradley, P., Pragalos, A., Bloch, M., Santiaguel, J., Frias, M. V., Miyakis, S., Alves de Mesquita, M., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2408863 · Cited by 8
“19 22 In addition, this vaccine platform could be easily adapted to express different antigens or antigen combinations, thus allowing the potential development of multivalent or universal vaccines against different pathogens.”
BackgroundThe solid organ transplant recipient with SARS-CoV-2 infection
Laracy, J. C., Miko, B. A., & Pereira, M. R. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000888 · Cited by 8
Nogawa, S., Kanamori, H., Tokuda, K., Kawafune, K., Chijiiwa, M., Saito, K., & Takahashi, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-47632-5 · Cited by 17
“This is consistent with the results of previous studies 8,23 .”
Constructing Artificial Nucleobase Compilation to Enable Precise Molecular Medicine†
Chen, J., Liu, B., Wang, X., Liu, X., Yang, D., & Yang, Y. P. (2023) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202200719 · Cited by 8
Global burden of vaccine-associated kidney injury using an international pharmacovigilance database
Hwang, H. S., Lee, H., Yoon, S., Kim, J. S., Jeong, K.-H., Kronbichler, A., Kim, H. J., Kim, M. S., Rahmati, M., Shin, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-88713-x · Cited by 9
Hassan, Y. A., Ali, M. D., Al-Eid, R. R., Al-Ghuraya, F. A., Alqasimi, Z. E., Ahmad, A., Eltrafi, Z., & Ghosn, S. A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.009 · Cited by 8
“The Pfizer-BioNTech/BNT162b2 vaccine is an mRNA vaccine that works by encoding the SARS-CoV-2 spike glycoprotein with its nucleoside mRNA and is prepared as a lipid-based nanoparticle drug delivery system for its efficient extravasation into host cells [9].”
BackgroundResultInfluentialJeon, H.-E., Lee, S., Lee, J., Roh, G., Park, H., Lee, Y., Kim, Y. J., Kim, H., Shin, J.-H., Lee, Y.-J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311726 · Cited by 10
RetractedSelf-replicating messenger RNA based cancer immunotherapy
Lyerly, H. K. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00619-w · Cited by 8
“Indeed, mRNA packaged into LNPs formed the basis for successful vaccines generated to prevent illness from COVID19 [4].”
BackgroundKaabi, N. A., Yang, Y., Hussein, S. E., Yang, T., Abdalla, J., Wang, H., Lou, Z., Bakkour, A. E., Arafat, A., Jiang, Z., et al. (2023) · Vaccines · doi:10.3390/vaccines11020299 · Cited by 8
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.